欧美自拍另类欧美宗合图片区,国产视频一区二区三区四区,日本一区二区三区四区视频,婬片一区AAA毛片一区二区

商品編號


AG-40B-0155-3010



品牌


Adipogen



公司


Adipogen



公司分類(lèi)


Proteins



Size

3 x 10 ?g


商品信息


More Information



Product Details



Synonyms

Nrg4



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Human Neuregulin-4 (aa 1-53) is fused at the N-terminus to GST.



Crossreactivity

Human



BIOLOG
ical Activity

Binds to the human receptor tyrosine-protein kinase ErbB4.



MW

~32kDa (SDS-PAGE)



Purity

≥95% (SDS-PAGE)



Endotoxin Content

<0.01eu mu;g="" purified="" protein="" (lal="" test;="" lonza).="">0.01eu>



Concentration

0.1mg/ml after reconstitution.



Reconstitution

Reconstitute with 100μl sterile water.



Formulation

Lyophilized. Contains PBS.



Other Product Data

UniProt link Q8WWG1:
Neuregulin-4 (human)




Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.



Use/St
ABI
lity

Stable for at least 6 months after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





Neuregulin-4 (Nrg4) belongs to a small family of EGF-like (EGFL) domain-containing proteins that are synthesized as transmembrane precursors and undergo proteolytic cleavage. The EGF-like domain (aa 5-46) of Nrg4 (aa 1-53) directly binds to the receptors ErbB3 and 4. Nrg4 is a cold induced
ADI
pokine, highly expressed in
ADI
pose tissues and enriched in brown fat. It is increased during brown
ADI
pocyte differentiation and reduced in rodent and human obesity. It promotes neurite outgrowth and protects against diet-induced insulin resistance and hepatic steatosis through attenuating hepatic lipogenic signaling. This hepatic effect of Nrg4 is mediated by ErbB3 and ErbB4 signaling that negatively regulates
de novo
lipogenesis mediated by LXR and SREBP1c. This effect of Nrg4 on fatty liver and insulin resistance could lead to the development of Nrg4 as an effective therapeutic
BIOLOG
ical for the treatment of NAFLD and type 2 diabetes. GST-Nrg4 (aa 1-53) recombinant protein has been shown to mimic the effect of endogenous secreted Nrg4 on liver lipogenesis.